Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis

Haemophilia

Volumn 16, Issue 6, 2010, Pages 919-925

  Othman, M ^a   Powell, S ^a   Hopman, W M ^b   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Canine; Haemophilia A; RFVIIa; TEG

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD SAMPLING; DOG; DRUG BLOOD LEVEL; GENETIC VARIABILITY; HEMOPHILIA A; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY;

ANIMALS; BLOOD CELL COUNT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOG DISEASES; DOGS; FACTOR VIIA; HEMOPHILIA A; HEMOSTASIS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 78049314907     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02336.x     Document Type: Article

References (32)

1. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
2. Hoffman M. A cell-based model of haemostasis. Blood Rev 2003; 17(suppl 1): S1-5.
3. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
4. Uhlmann EJ, Eby CS. Recombinant activated factor VIII for nonhemophiliac bleeding patients. Curr Opin Hematol 2004; 11: 198-204.
5. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004; 18: 245-59.
6. Hedner U. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Dis Mon 2003; 49: 39-48.
7. Van Den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007; 5(Suppl 1): 151-6.
8. Massimo Franchini. Recombinant factor VIIa: a review on its clinical use Massimo Franchini. Int J Hematol 2006; 83: 126-38.
9. Young G, Ebbesen LS, Viuff D et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
10. Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost 1995; 21(Suppl 4): 34-44.
11. Tuman KJ, McCarthy RJ, Djuric M, Rizzo V, Ivankovich AD. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth 1994; 8: 144-9.
12. Sharma SK, Vera RL, Stegall WC, Whitten CW. Management of a postpartum coagulopathy using thrombelastography. J Clin Anesth 1997; 9: 243-7.
13. Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42: 716-20; discussion 720.
14. Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997; 130: 401-11.
15. Kawaguchi C, Takahashi Y, Hanesaka Y, Yoshioka A. The in vitro analysis of the coagulation mechanism of activated factor VII using thrombelastogram. Thromb Haemost 2002; 88: 768-72.
16. Hayashi T, Tanaka I, Shima M et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10: 397-400.
17. Koestenberger M, Gallistl S, Muntean W, Ferstl U, Kutschera J, Cvirn G. An evaluation of the procoagulant action of recombinant activated factor VII in cord whole blood versus adult whole blood using thromboelastography. Blood Coagul Fibrinolysis 2005; 16: 613-7.
18. Young G. New approaches in the management of inhibitor patients. Acta Haematol 2006; 115: 172-9.
19. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
20. Goudemand J, Caron C, Dreyfus M, Sie P. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagul Fibrinolysis 2003; 14: 505-11.
21. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
22. Wiinberg B, Jensen AL, Rojkjaer R, Johansson P, Kjelgaard-Hansen M, Kristensen AT. Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. Vet Clin Pathol 2005; 34: 389-93.
23. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: 2039-43.
24. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia, 2007; 13: 451-61.
25. Schulman S, D'Oiron R, Martinowitz U et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S97-101.
26. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
27. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
28. Ng HJ, Lee LH. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag 2006; 2: 433-40.
29. Kristensen AT, Wiinberg B, Jessen LR, Andreasen E, Jensen AL. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. J Vet Intern Med 2008; 22: 140-7.
30. Wiinberg B, Jensen AL, Rozanski E et al. Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs. Vet J. 2009; 179: 121-9.
31. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and parmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
32. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008; 1: 3-11.